Clariness announces its multi-year partnership with Boehringer Ingelheim Pharma & Co to digitally engage and recruit patients through its patient portal, ClinLife®.
Boehringer Ingelheim for many years had leveraged Viomedo, a patient portal that Clariness acquired in 2018. In 2021, Boehringer Ingelheim expanded its patient enrolment strategy through ClinLife®, leveraging Clariness’ unique digital targeting and trial matching techniques. After many years of working with Viomedo, Boehringer Ingelheim agreed to a multi-year partnership to advance its digital recruitment through ClinLife®.
Moritz Kloss, vice-president of ClinLife Registry at Clariness, said “We are proud to continue our cooperation and partnership with Boehringer Ingelheim. Over the last few months, ClinLife® has proven successful in matching the right patients, with suitable clinical studies across multiple indications. This is one of many steps to make clinical trials more accessible and patient-friendly, and advance medical progress.”
This multi-year agreement will allow Clariness to develop new ways of digitally targeting and engaging patients, while accelerating Boehringer Ingelheim’s patient enrolment strategy.